Taking peoplePhase 2
Testosterone Replacement Therapy in Women with Turner Syndrome
Key facts
- Who runs it
- Region Midtjylland
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- 26 Feb 2026
- Expected to end
- 5 Feb 2029
- Type of study
- Interventional
- Record updated
- 23 March 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Turner Syndrome (all karyotypes)
- Age between 18 and 50 years (both included)
- Receiving estrogen replacement therapy
- Speaking Danish
Who cannot take part
- Previous stroke, acute myocardial infarction or venous thromboembolism
- Former or present untreated or uncontrolled chronic disease
- Diagnosed breast, cervical or endometrial cancer
- Allergy to the drug used
- Grave obesity (BMI > 40)
- Heavy smoking (> 20 cigarettes/day)
- Levels of androgen above normative levels
- Pregnancy and lactation
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objective of this study is to evaluate the endocrine, physiological, cardiovascular neurocognitive, and genomic effects of transdermal TRT, as a supplement to ERT, in women with TS.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Testosterone Replacement Therapy in Women with Turner Syndrome – Endocrine, Cardiovascular, Physiological, Neurocognitive and Genomic effects
- Fit questions
- Built from 2024-517755-12-00, who can take part
- Record updated
- 23 March 2026